Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Endeavor Biomedicines, Inc.
Eli Lilly and Company
Children's Oncology Group
Seattle Children's Hospital
Milton S. Hershey Medical Center
Institut Curie
Massachusetts General Hospital
The Hospital for Sick Children
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
University of Florida
The University of Texas Health Science Center, Houston
City of Hope Medical Center
The University of Texas Health Science Center, Houston
St. Jude Children's Research Hospital
Children's Oncology Group
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Celgene
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Washington University School of Medicine
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Mayo Clinic
Emory University
University of Iowa
Children's Oncology Group
Children's Cancer Hospital Egypt 57357
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
University of Colorado, Denver
Wake Forest University Health Sciences
University of Iowa
Wake Forest University Health Sciences
Pediatric Brain Tumor Consortium
Children's Cancer Hospital Egypt 57357